What to Know About Syfovre and Izervay for Geographic Atrophy
WEBFeb 18, 2024 · Two new drugs – Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) – were approved in 2023 for geographic atrophy, a potentially debilitating type of dry age-related macular degeneration (AMD). The disease affects about one million Americans and can lead to significant vision loss.
Which is better: Syfovre or Izervay? - Scott E. Pautler, M.D ...
WEBDec 17, 2023 · Syfovre and Izervay are not cures for dry AMD. They do not reverse the past damage by geographic atrophy. Syfovre and Izervay, when given by monthly injection, was shown to reduce the rate of worsening of geographic atrophy by a …
How do Izervay and Syfovre compare? - Drugs.com
WEBMay 27, 2024 · Izervay (avacincaptad pegol) and Syfovre (pegcetacoplan) are injectable treatments for geographic atrophy (GA), a severe form of age-related macular degeneration (AMD) that causes progressive and irreversible vision …
In This Syfovre-Izervay Comparison, Syfovre Gets the Nod | ASRS …
WEBJul 18, 2024 · In the comparison of monthly injections, Syfovre produced a statistically significant 30% greater reduction in the growth of the geographic atrophy lesion than Izervay did after a year of treatment and Syfovre advantage persisted during a second year of treatment, according to results shared by Hahn.
The geographic atrophy treatment battle: Syfovre vs. Izervay
WEBNov 22, 2023 · In this article, we take a look at the events surrounding the historical approvals of the first two geographic atrophy treatments, and the ensuing rivalry between Apellis’ Syfovre and Astellas’ Izervay.
New Treatments for Geographic Atrophy: What You Need to Know
WEBSep 26, 2023 · Two treatments for geographic atrophy, Syfovre and Izervay, were approved in 2023. Learn how they work and whether you’re a candidate for using them.
Two Rival Treatments Approved for Geographic Atrophy Under …
WEBSep 1, 2023 · IZERVAY is a complement factor C5 inhibitor and was recently approved as a treatment for GA. It blocks the complement factor cascade further downstream compared to SYFOVRE. The GATHER1 and GATHER2 trials showed a 35% reduction of GA lesion growth over 6 months.
Story of discovery: NEI-funded research paves way for new dry …
WEBDec 12, 2023 · This year, the Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), the very first drugs for treating geographic atrophy (GA), also known as late-stage …
Second Geographic Atrophy Treatment Receives FDA Approval
WEBAug 8, 2023 · Izervay (avacincaptad pegol intravitreal solution), a new treatment to slow the progression of the advanced and severe form of age-related macular degeneration known as geographic atrophy (GA), has received full FDA approval, and is expected to be available within a month in the U.S.
FDA Approves Izervay: New Drug Slows Progression of …
WEBAug 16, 2023 · Both Izervay and Syfovre inhibit the overactivation of one of the roughly 50 biochemical compounds found in the complement system, which mobilizes proteins to battle invading pathogens.